arrow-circle-full-right arrow-circle-full-up arrow-circle-up arrow-down arrow-right calendar calendar-done facebook flickr home linkedin login pin reload search share signin star twitter video video youtube nav star-plus info signout double-arrow arrow-up checked
Healthcare & Life Sciences

FT Global Pharmaceutical and Biotechnology Conference

London |
Speakers include:
Marie-France Tschudin

Marie-France Tschudin

Novartis

Stefan Oelrich

Stefan Oelrich

Bayer AG

Karenann  Terrell

Karenann Terrell

GlaxoSmithKline

Overview

Disruption and transformation will continue to be the focus of life science leaders in 2019 and beyond. 

Pricing pressures in the US and a growing number of markets globally have already set in motion a search for new and innovative payment models, while the rise of ultra-expensive, potentially curative gene and cell therapies has brought to the fore a heated discussion about the sustainability of the industry’s underlying economic and funding model.

With a host of ‘new entrants’ in the shape of big tech and consumer-centric start-ups nibbling at pharma’s heels in the emerging prevention and wellness space, meanwhile, pharma faces competition on an increasing number of fronts. Success in the new data and patient-centric world which is emerging will increasingly depend on forging relationships with patients sustained on trust, and building new business models for the future.

fallback
fallback Add to my Calendar 11/11/2019 13:15:0011/12/2019 17:30:00trueFT Global Pharmaceutical and Biotechnology ConferenceDisruption and transformation will continue to be the focus of life science leaders in 2019 and beyond. Pricing pressures in the US and a growing number of markets globally have already set in motion a search for new and innovative payment models, while the rise of ultra-expensive, potentially curative gene and cell therapies has brought to the fore a heated discussion about the sustainability of the industry’s underlying economic and funding model.With a host of ‘new entrants’ in the shape of big tech and consumer-centric start-ups nibbling at pharma’s heels in the emerging prevention and wellness space, meanwhile, pharma faces competition on an increasing number of fronts. Success in the new data and patient-centric world which is emerging will increasingly depend on forging relationships with patients sustained on trust, and building new business models for the future.FT-Global-Pharmaceutical-and-Biotechnology-Conference4da62f606ea64163d2a341ae0a173256MM/DD/YYYY

2018 Photos

fallback

Speakers (44)

Marie-France Tschudin

Marie-France Tschudin

President Pharmaceuticals
Novartis
Stefan Oelrich

Stefan Oelrich

Member of the Board of Management and President Pharmaceuticals
Bayer AG

Stefan Oelrich is a member of the Board of Management of Bayer AG and President of its Pharmaceuticals Division, a position he has held since November 2018. Prior to joining the company, he was on the Executive Committee of Sanofi, leading its global Diabetes & Cardiovascular business. During his seven-year tenure, he was also at the helm of Sanofi Germany, Switzerland and Austria, as well as the Diabetes and Cardiovascular business unit in Europe. From 1989 to 2011, Mr Oelrich held various leadership positions in the health care business of Bayer AG with extensive international experience spanning Latin America (Argentina, Uruguay), Europe (France, Belgium) and the United States. Mr Oelrich is a member of the Supervisory Board of the Berlin Institute of Health and member of the Board of the American Chamber of Commerce in Germany.

Karenann  Terrell

Karenann Terrell

Chief Digital & Technology Officer
GlaxoSmithKline

Karenann Terrell joined GSK as Chief Digital & Technology Officer in September 2017 with a company-wide remit to transform how new technologies are used to improve performance across the Group. She is a member of the Corporate Executive Team. She is responsible for GSK’s digital, data and analytics strategy, working with a wide range of partners from inside and outside the healthcare sector to bring new technologies to GSK, enhancing areas such as clinical trials and drug development; improving how the Group interacts with healthcare professionals, customers and consumers; and making internal processes more efficient. Ms Terrell’s previous role was Chief Information Officer for Walmart, where she led a multi-year effort to transform Walmart in the use of data, analytics and digital engagement with its customers. Prior to Walmart she was at Baxter International, where she was Chief Information Officer, and before that DaimlerChrysler. Ms Terrell began her career in General Motors and held various roles in manufacturing, engineering and brand management. She is a member of the board of trustees for the New York Hall of Science, a hands-on science and technology centre. She earned graduate and post-graduate degrees in Electrical Engineering from Kettering University and Purdue University, respectively.

Jackie Hunter

Jackie Hunter

Board Director
Benevolent AI

Jackie Hunter has over thirty years of experience in the bioscience research sector, working across academia and industry including leading neurology and gastrointestinal drug discovery and early clinical development for GlaxoSmithKline.   On leaving GSK, Professor Hunter established OI PharmaPartners Ltd to drive innovation in Life Sciences and set up a spinout company to spin assets out of Big Pharma with VC funding. Before joining BenevolentAI, Professor Hunter was CEO of the Biotechnology and Biological Sciences Research Council (BBSRC). BBSRC distributed over £500m p.a. to fund basic bioscience and its translation in areas such as biotechnology, veterinary medicine and bioenergy. Professor Hunter was awarded a CBE in the Queen's Birthday Honours list in 2010 for Services to the Pharmaceutical Industry and was recently recognised by Forbes Magazine as one of the top 20 Women Advancing AI Research.  She is a member of the Biomedical Board for A*Star in Singapore, the Science Advisory Board for the Data Science Institute at Imperial College, London and a Board Director of the UK Bio-Industry Association as well as a participant of numerous grant panels and reviews for funders.   She is also a visiting Professor at Imperial College and at St Georges Hospital Medical School.

Lord Drayson PhD

Lord Drayson PhD

Chief Executive Officer
Sensyne Health

Lord Drayson is an engineer and science entrepreneur. Following his PhD in robotics he has over 25 years of experience in founding and leading successful businesses built on science and technology. His latest venture is Sensyne Health plc, a Clinical Artificial Intelligence company, which listed on the AIM market of the London Stock Exchange in August 2018. In addition to his experience as a science entrepreneur, he was a Defence Minister and Minister for Science and Innovation in the UK Government between 2005 and 2010 following his appointment to the House of Lords in 2004. He is a member of Her Majesty’s Privy Council, a Fellow of the Institution of Engineering and Technology, a Fellow of the Royal Academy of Engineering, an Honorary Fellow of the Academy of Medical Sciences and a non-executive director of Airbus. He is passionate about motorsport and currently holds three world land speed records for electric vehicles.

Kåre  Schultz

Kåre Schultz

President and CEO
Teva

Kåre Schultz became Teva's President and CEO in November 2017. Mr Schultz is a seasoned veteran in the healthcare industry who has distinguished himself through his experience leading financial and restructuring initiatives at global companies. From 2015 to, 2017 he has served as the President and Chief Executive Officer of H. Lundbeck A/S, which he joined as the company was facing the loss of critical patents. Mr Schultz conducted a top to bottom evaluation of the business and implemented a robust turnaround strategy that involved cutting operating costs while targeting new product launches. Prior to joining Lundbeck, Mr Schultz worked for nearly three decades at Novo Nordisk, where he served in a number of leadership roles, including Chief Operating Officer, Vice President in Product Supply and Director of Product Planning and Customer Services in the Diabetes Care Division. At Novo Nordisk, Mr Schultz played a major role in modernizing the company’s large scale biologic production and leading the company’s expansion into the US and Chinese markets. In addition to his time at Novo Nordisk, Mr Schultz has held positions at McKinsey and Anderson Consulting. In these roles, he developed a unique global perspective on the healthcare and pharmaceutical industries, expanded his deep financial acumen, demonstrated a commitment to strong compliance principles and enforcement and oversaw business operations and teams across Europe and North America and the Middle East. Mr Schultz serves as a member of the Board of Directors of LEGO A/S. He also served as the Chairman of the Board of Directors of Royal Unibrew A/S, and as a member of the Board of Directors of Bitten og Mads Clausens Fond, the holding vehicle for Danfoss A/S. He holds a Master’s degree in Economics from the University of Copenhagen.

Camilla Sylvest

Camilla Sylvest

Executive Vice President, Commercial Strategy and Corporate Affairs
Novo Nordisk

Camilla Sylvest is Executive Vice President, Commercial Strategy & Corporate Affairs of Novo Nordisk. She joined Novo Nordisk in 1996 as a trainee. From 1997 to 2008 she held roles in the headquarters and in the regions within pricing, health economics, marketing and sales effectiveness. In 2003, she was appointed Vice President of Sales and Marketing Effectiveness in Region Europe. From 2008 to 2015, Ms Sylvest headed up affiliates and business areas of growing size and complexity in Europe and Asia, and in 2013 she was also appointed Corporate Vice President. In August 2015, she was appointed Senior Vice President and General Manager of Novo Nordisk’s Region China. In this role she was responsible for the company’s activities in China, Taiwan and Hong Kong. In October 2017, she was promoted to Executive Vice President.Ms Sylvest serves as member of the board of Danish Crown A/S, Denmark. She holds an MSc in Economics from University of Southern Denmark and an Executive MBA from Scandinavian International Management Institute. Ms Sylvest serves as member of the board of Danish Crown A/S, Denmark. She holds an MSc in Economics from University of Southern Denmark and an Executive MBA from Scandinavian International Management Institute.

Virginia Acha

Virginia Acha

Executive Director-Global Regulatory Policy, R&D Innovation Centre
MSD

Virginia (Ginny) Acha has worked in industry and academia throughout her career, combining interests in science policy research and innovation performance within and across organisations.  She recently joined MSD to lead regulatory policy efforts for innovation that will lead to better treatment for patients in Europe, the Middle East, Africa and Asia.  In particular, she is supporting work on real world evidence and integrated evidence generation. Before joining MSD, Dr Acha was the senior spokesman for the industry in the UK for research, medical and innovation policy.  She was responsible for ABPI’s work on Brexit for the life sciences sector.  Previously, Dr Acha worked for Amgen in global regulatory policy and for Pfizer working on policy development in science and innovation in healthcare. 

Alexandra Bause

Alexandra Bause

Founding Partner
Apollo Ventures

Alexandra Bause is a founding member and partner at Apollo Ventures, a biotech company builder and investment fund focused on developing interventions to improve human health and longevity. At Apollo, Ms Buase is leading the venture creation programmes that aim to found new biotech startups targeting the ageing process at a molecular level. She is also managing the pipeline and diligence process for external investment opportunities, predominantly focusing on preclinical-stage biotech companies. 

Before joining Apollo Ventures, Ms Bause worked with The Boston Consulting Group where she specialised in biopharma strategy, market assessment and asset diligence. Her PhD studies at Harvard Medical School were focused on investigating the molecular mechanisms that contribute to cellular aging and could be targeted to increase mammalian health span. She is also a trained pharmacist with expertise in pharmaceutics and pharmacology.

Alexis Borisy

Alexis Borisy

Partner
Third Rock Ventures

Alexis Borisy is a leading biotechnology entrepreneur and investor with more than 25 years  of experience building, operating and investing in innovative science-based companies to  make a positive difference in the world. Mr Borisy co-founded Foundation Medicine (FMI), served as its first CEO, and then chairman, remaining on the board until the $5bn acquisition by Roche. He also co-founded Blueprint Medicines, served as interim CEO, and continues to serve on the board. As a partner at Third Rock Ventures for a decade, Mr Borisy also was a founding investor for Editas and Magenta Therapeutics; a co-founder, former CEO, and Chairman of Relay Therapeutics; Chairman of Tango Therapeutics and Chairman of Celsius Therapeutics; and an investor in Insitro, among others.  He founded his first company, CombinatoRx, when he was in his 20s, served as its CEO and brought the company public on the NASDAQ.  Trained in chemistry and chemical biology at Harvard, Mr Borisy has authored scientific papers and patents, and was honoured as the MIT’s Technology Review Innovator of the Year. He is Vice Chairman of the Board of Trustees of the Boston Museum of Science,  has served on the board of BIO, and currently serves as the Chairman of the National  Venture Capital Association.

Christopher Boerner

Christopher Boerner

Executive Vice President and Chief Commercial Officer
Bristol-Myers Squibb

Christopher Boerner is currently Executive Vice President and Chief Commercial Officer at Bristol-Myers Squibb (BMS). Prior to this he was Head of International Markets and accountable for commercial activities in all ex-US markets. This followed a position as the company's  Head of the US Commercial business. He joined BMS in February 2015. Prior to joining BMS, Dr Boerner served as the Executive Vice President of Commercial for Seattle Genetics, Inc., where he led all commercial activities for the company. Previously, he was its Senior Vice President of Commercial and its Vice President of Marketing. Before joining Seattle Genetics, he was with Dendreon Corporation, where he led the marketing team. From 2002 to 2010, he was with Genentech, a member of the Roche Group, where he served in a variety of commercial roles, including Director of Marketing on Avastin, Director of Avastin franchise strategy and Associate Director of Oncology Market Development. Prior to Genentech, he was with McKinsey & Company, a global strategic management consulting firm, where he served global pharmaceutical and biotechnology clients.Dr Boerner received his PhD and MA in Business Administration from the Haas School of Business at the University of California, Berkeley, and holds an A.B. in Economics and History from Washington.

Heather  Bresch

Heather Bresch

Chief Executive Officer
Mylan

Heather Bresch is the Chief Executive Officer of Mylan. She also serves on the company’s board of directors. As CEO, she is responsible for a workforce of more than 35,000, a powerful global research and development platform, a manufacturing footprint comprising more than 4O facilities and a portfolio of more than 7,500 generic and branded pharmaceuticals sold in more than 165 countries and territories.  Throughout her more than 25-year career with Mylan, Ms Bresch, who started with the company as a data-entry clerk, has held roles of increasing responsibility in more than 15 functional areas. Prior to becoming CEO, she served as Mylan’s President, where she was responsible for the day-to-day operations of the company. Before that, she served as Mylan’s Chief Operating Officer and Chief Integration Officer, leading the successful integration of two international acquisitions – Matrix Laboratories and Merck KGaA’s generics business – which more than doubled the size of the company. Ms Bresch emphasizes a collaborative company culture focused on leading, learning, teaching and performing to inspire innovation and help set new standards in healthcare.

Bill Campbell

Bill Campbell

Executive Vice President, Chief Commercial Officer
CSL Behring

Bill Campbell is Executive Vice President, Chief Commercial Officer of CSL Behring. In this role, he is responsible for a variety of global functions including sales, marketing, commercial development, medical affairs and public policy. Prior to being appointed to his current position in 2017, Mr Campbell led CSL Behring’s North American commercial operations since joining the company in 2014. He has more than 35 years of diverse experience across a range of therapeutic areas including, oncology, pain care and vaccines and has held senior management positions at a number of pharmaceutical and biotechnology companies. Mr Campbell holds a Bachelor of Science degree in Business Administration from Western Michigan University.

Joaquin Duato

Joaquin Duato

Vice Chairman
Johnson & Johnson

As Vice Chairman of the Johnson & Johnson Executive Committee, Joaquin Duato is responsible for the Company’s Pharmaceuticals and Consumer sectors, as well as Supply Chain, Information Technology, Global Services, and Health & Wellness. He is a respected industry leader and the immediate past Chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA).

Mr Duato played an instrumental role in leading the turnaround of the Johnson & Johnson Pharmaceuticals division. A 30-year veteran of the company, Mr Duato was named Company Group Chairman of the Americas in 2009 and Executive Vice President and Worldwide Chairman, Pharmaceuticals in 2011. During that time, the business grew into what is today the fourth-largest innovative pharmaceutical company globally.

As a dual citizen of Spain and the United States with experience on multiple continents, Mr Duato brings a unique international perspective. His commitment to diversity was recognized in 2017 by the Healthcare Businesswomen’s Association when he was named 2017 Honorable Mentor. Mr Duato holds an undergraduate degree in Economics and Business, a Master of Business Administration degree from ESADE Business School in Barcelona, Spain, and a Master of International Management degree from Thunderbird in Phoenix, Arizona. He recently completed his term as Board Member of Save the Children.

Marc Funk

Marc Funk

Chief Executive Officer
Lonza Group

In January 2019, Marc Funk was appointed as CEO of Lonza Group Ltd, effective 1 March 2019. In his former role as President and COO of the Lonza Pharma & Biotech segment, Mr Funk led the business through significant operational transformation and major expansions in capacity and capability. His responsibilities included driving innovation in biopharma manufacturing through an extensive R&D program, as well as attracting and developing talent as part of the segment growth strategy.  From 2009 to 2014, Mr Funk served as General Counsel and Board Secretary of Lonza Group Ltd.  Prior to joining Lonza, Mr Funk served as Associate General Counsel of Merck Serono (formerly Serono) from 2004 to 2008, and from 2000  to 2004 as Co-CEO and General Counsel of GeneProt. Mr Funk has a Master of Law degree from the University of Geneva and a Master of Law and Diplomacy degree from the Fletcher School (Tufts University, MA).

Andy Garrett

Andy Garrett

Executive Vice President, Scientific Operations
ICON

Andrew Garrett is Executive Vice President Scientific Operations at ICON, responsible for strategic direction and operational execution of ICON’s Global Scientific Operations. He was Chair and Founder of the Royal Statistical Society’s (RSS) Data Science Section having previously been VP/Honorary Secretary of the organisation, and Chair of its Long Term Strategy Group. He was previously a Board member of the UK’s Administrative Data Research Network and is currently a member of UKSA’s Research Accreditation Panel that oversees the approval of research projects in accordance with the Digital Economy Act 2018. He has worked extensively in the area of rare diseases and has a portfolio of published papers on the topics of non-inferiority trials, subgroup analysis, data transparency and modelling and simulation. Dr Garrett has a BSc in Economics, an MSc in Medical Statistics and a PhD in Applied Statistics.

Angus  Grant

Angus Grant

CEO
Dementia Discovery Fund

Angus Grant is the Chief Executive Officer of the Dementia Discovery Fund ( DDF), a specialist venture capital fund managed by SV Health Managers LLP that invests in novel science to create meaningful new medicines for dementia. Prior to joining the DDF, Dr Grant worked at Celgene for almost 12 years.  He started at Celgene as Vice President North American Regulatory Affairs in 2006, in the Summit NJ Headquarters.  In 2008, he moved to London as Head of Europe RA for three years to build out the function. Dr Grant returned to the Summit NJ Headquarters as Vice President, Business Development and Global Alliances, in 2011, where he completed multiple innovative deals spanning discovery and late stage clinical assets as well as M&A. In tandem, he built the Alliance Management function, managing over 60 collaborations and investments with pharmaceutical and biotech partners. In 2016, Dr Grant focused on deals, serving as Corporate Vice President of Business Development, leading the Business Development team running the transactions from deal inception to close before leaving Celgene for the DDF.  Angus previously worked at Novartis, Merck KGaA, Rhone Poulanc-Rohrer, SmithKline Beecham, and the US Food and Drug Administration. Dr Grant received his undergraduate degree from the University of Richmond, then his PhD in Anatomy & Immunology from the Medical College of Virginia and completed his post-doctoral training at the National Cancer Institute in Bethesda.  Outside of SV Health, Dr Grant sits on the Board of MaRS Innovation and Rheostat Therapeutics.

Yvonne Greenstreet

Yvonne Greenstreet

Chief Operating Officer
Alnylam

Yvonne Greenstreet has over 25 years of global experience in the pharmaceutical industry, where she has been in senior roles in research and development, strategy, and portfolio management. She has successfully led product development and commercialisation teams in a wide range of therapy areas, and bringing new medicines to patients. Dr Greenstreet was previously Senior Vice President and Head of Medicines Development at Pfizer, and a member of the executive team for the specialty business, with accountability for a portfolio that included the immuno-inflammation, vaccine, specialty neuroscience, and rare disease areas. Prior to Pfizer, she held roles of increasing responsibility at GlaxoSmithKline, including Senior Vice President and Chief of Strategy for Research and Development, Senior Vice President for Medicines Development and Chief Medical Officer for Europe. Dr Greenstreet received her medical degree (MBChB) from the University of Leeds, UK, and an MBA degree from INSEAD, France. She serves as a member of the board of directors of Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, and Indivior PLC, a global specialty pharmaceutical business. Dr Greenstreet also serves on the Scientific Advisory Committee of the Bill and Melinda Gates Foundation.

Mark  Hammond

Mark Hammond

Founding Partner
Deep Science Ventures

Mark Hammond is a Founding Partner at Deep Science Ventures (DSV). DSV’s mission is to scale the impact of science by systematically identifying venture scale opportunities, across sectors from oncology to energy storage. This is achieved by identifying the current constraints, designing and building what is considered the ‘holy grail’ venture in each sector. After initially undertaking a PhD in Neuropharmacology and Artificial Intelligence, Dr Hammond worked in cleantech venture before going on to build out Imperial College’s deep-tech start-up accelerator and academic spin-out ecosystem.

Mark Howells

Mark Howells

Vice President, Global Talent and Development
AstraZeneca

Marc Howells is Vice President, Global Talent and Development, AstraZeneca. In this role, he is accountable for leading the enterprise strategies associated with leadership development, learning transformation, talent, workforce insights and analytics, and organisational development. Prior to taking up this position in October 2018, Mr Howells spent 2 years leading the North America Commercial HR agenda. During this time Marc supported the business through a period of significant business change, key commercial launches, and establishment of the inclusion & diversity strategy. Between 2013 and 2016, Mr Howells was the Vice President for Global Operations, Corporate Enabling Units and the Japan market.  Although having spent most of his career in HR leadership roles, Mr Howells also spent 5 years working in supply chain in Asia Pacific as the VP Supply & Manufacturing for Australia and NZ, and latterly as the VP Supply & Manufacturing for China, heading up supply chain and leading one of AstraZeneca’s largest manufacturing sites. Other roles Mr Howells has held in both in HR and business leadership since joining AstraZeneca in 2014 include VP Global Commercial Supply, responsible for the end to end tactical and strategic commercial supply chain for all globally launched brands and Global Director of Talent & Strategic Workforce Planning and Specialist HR Lead for Global Operations, Drug Development & Discovery Research.

Bahija Jallal

Bahija Jallal

CEO
Immunocore

Bahija Jallal is Chief Executive Officer and Director of the Board of Immunocore, the leading T-Cell Receptor (TCR) biotechnology company. Prior to joining Immunocore in January 2019, she was President of MedImmune, Astra Zeneca’s global biologics research and development unit. She was also Executive Vice President of AstraZeneca and a member of its senior executive team. Dr Jallal serves on the Board of Anthem, Inc. and is a member of the Board of Trustees of the Johns Hopkins University and the Board of Directors of the University of Maryland Health Sciences Research Park Corporation. She also served as Chairman of the Board of Viela Bio in 2018. Dr Jallal has authored over 70 peer-reviewed publications and has more than 15 patents. She is a Council Member of the Government-University-Industry Research Roundtable of the National Academies of Sciences, Engineering and Medicine and a member of the American Association of Science. She is also the immediate past President of the Association of Women in Science. Dr Jallal was named the 2017 Woman of the Year by the Healthcare Businesswomen’s Association. Prior to joining MedImmune, Dr Jallal worked with Chiron Corporation where she served as Vice President, Drug Assessment and Development, and successfully established the company’s translational medicine group. Prior to Chiron Corporation, she worked at Sugen, Inc.Dr Jallal received a Master’s degree in Biology from the Universite de Paris VII in France, and her doctorate in Physiology from the University of Pierre & Marie Curie in Paris. She conducted her postdoctoral research at the Max-Planck Institute of Biochemistry in Martinsried, Germany.

Harpal Kumar

Harpal Kumar

Head of Innovation, EMEA
Johnson & Johnson

 

Sir Harpal Kumar is the Head of Johnson & Johnson Innovation EMEA, based at the Innovation Center in London. He oversees a portfolio of co-investments and collaborations across the region and works to grow the Innovation Center’s networks within the EMEA innovation community – which includes working, and building relationships with academia, venture capital, entrepreneurs, NGOs, and governmental organisations.

Before joining Johnson & Johnson Innovation, Sir Harpal’s career has been largely focused on improving healthcare outcomes through innovation. He spent 15 years with Cancer Research UK (CRUK) and served as the organisation’s Chief Executive from April 2007 until June 2018. Prior to this, he was Chief Operating Officer & Executive Director of Development at CRUK and served as Chief Executive of Cancer Research Technology (a subsidiary of CRUK).

Sir Harpal also served as CEO of The Papworth Trust, which focuses on pioneering rehabilitation services for people with acquired and congenital disabilities. He left this role in 1997 to become founding CEO of Nexan Group, a venture capital-backed medical device company, creating and marketing novel cardio-respiratory monitoring technologies to reduce premature mortality in patients with congestive heart failure.

Sir Harpal was Chair of the Taskforce and author of “Achieving World-Class Cancer Outcomes: A Strategy for England 2015-2020”, published in summer 2015. He is a Non-Executive Board member of UK Research & Innovation (UKRI) and the Senior Independent Director of Innovate UK.

Sir Harpal gained a Master’s degree in Chemical Engineering from the University of Cambridge, and an MBA as a Baker Scholar from Harvard Business School. He has been awarded Honorary Doctorates from the Universities of Manchester, Newcastle and Glasgow and the Institute of Cancer Research and he is a Fellow of The Academy of Medical Sciences.  In 2016, he was knighted by Her Majesty Queen Elizabeth II for services to cancer research.

Brad Loncar

Brad Loncar

CEO
Loncar Investments

Brad Loncar is an independent biotechnology investor and CEO of Loncar Investments, a firm that specialises in the creation of thematic biotechnology investment indexes. Its first two products are The Cancer Immunotherapy Index and The China BioPharma Index. Mr Loncar previously worked in the financial services industry at Franklin Templeton Investments, where he was a member of the Management Training Program, and was appointed to serve in a Senior Advisor role at the U.S. Department of the Treasury. He currently writes biotechnology commentary at www.LoncarBlog.com, is one of the most followed voices in biotech on social media, and has contributed opinion pieces to Endpoints News and Xconomy. Loncar Investments is an official charitable partner of the Cancer Research Institute.

Eddie Martucci

Eddie Martucci

Founder and CEO
Akili Interactive

Eddie Martucci is a Co-Founder and CEO of Akili Interactive, a leading digital therapeutics company creating prescription treatments for people living with cognitive disorders that are delivered through immersive action video game experiences. Akili is currently developing technologies to treat
medical conditions across neurology and psychiatry, including ADHD, depression, autism and various inflammatory diseases. Prior to starting Akili in 2011, Dr Martucci co-founded two other health- focused start-ups with PureTech Health and helped launch the firm’s digital health initiative. He was previously a Kauffman Entrepreneur Fellow, a programme sponsored by the Kauffman Foundation of Kansas City, MO, focused on healthcare entrepreneurship. Prior to that, he completed his graduate work at Yale University in the Departments of Pharmacology and Molecular Biophysics & Biochemistry. Dr Martucci received his B.S. in Biochemistry from Providence College, and his M.Phil. and PhD from Yale University. Dr Martucci frequently serves on discussion panels for industry and academic events related to healthcare innovation, has appeared in media including CNN’s Vital Signs with Sanjay Gupta and CNBC’s Modern Medicine. Akili has received recognition including the 2014 Future of Health Technology product award, 2015 50-on-Fire Boston, #1 health company in
Entrepreneur magazine’s 100 Brilliant Companies of 2016, CNS Summit 2017 Innovation Award winner, 2018 Xconomy Innovation at the Intersection award finalist, 2018 Bostonfest Coolest Companies finalist and 2018 Business Intelligence Best Places to Work finalist.

David Meek

David Meek

CEO
Ipsen

David Meek was appointed Ipsen’s CEO in 2016, and also serves on the company’s Board of Directors. He joined from Baxalta Inc, where he was Executive Vice-President and President of the Oncology division. Prior to this, he spent 14 years in the US at Johnson & Johnson and Janssen Pharmaceutica, in senior commercial roles across multiple therapeutic areas in specialty and primary care. He also served as Chief Commercial Officer of Endocyte, an oncology biotechnology company in the US.  Earlier in his career, Mr Meek was at Novartis for nine years, successively serving as a Global Business Franchise Head in Basel, Switzerland; President and CEO of Novartis Canada; and the Head of Oncology for Northern, Central and Eastern Europe based in Italy. Prior to his biopharma career, Mr Meek was an officer in the United States Army. He is a graduate of the University of Cincinnati.   

Justin McCarthy

Justin McCarthy

Senior Vice President, Patient and Health Impact Group
Pfizer

Justin McCarthy is Senior Vice President, Patient & Health Impact group, part of the Chief Business Office at Pfizer. The Patient & Health Impact group brings together experts in health economics and outcomes research, real-world data and analytics, patient-centered outcomes assessment, market access, pricing, strategy and contracting, who generate evidence of the value of Pfizer medicines and vaccines and negotiate with governments and payers in the US and around the world to ensure access for patients. This group is also leading Pfizer’s work to explore novel approaches to commercialise medicines through innovative partnerships and payment models.

Prior to this role, Mr McCarthy was Senior Vice President, Global Policy & International Public Affairs, responsible for defining Pfizer’s public policy positions on US healthcare at the federal and state level and advancing government and public affairs strategies internationally. Mr McCarthy has been with Pfizer for 25 years and was formerly Chief Counsel for Pfizer’s Worldwide Research and Development division, advising on regulatory, licensing and clinical trial issues, and overseeing global intellectual property activities. He has extensive experience negotiating Pfizer’s research collaborations and partnerships with government, academic institutions and biotechnology companies.

Mr McCarthy serves on the boards of the National Pharmaceutical Council, Vivli Inc. and sits on the Portfolio and Strategic Investment Committee (PSI) within Pfizer which is the company’s governance body that oversees the R&D investments and strategy.

Prior to joining Pfizer, Mr McCarthy was an associate in the law firm of Keller & Heckman. Mr McCarthy holds a Bachelor’s degree in Pharmacy from the University of Rhode Island and law degree from the Catholic University of America.

Pierre Meulien

Pierre Meulien

Executive Director
Innovative Medicines Initiative (IMI)
Nathalie Moll

Nathalie Moll

Director General
European Federation of Pharmaceutical Industries and Associations (EFPIA)

Nathalie Moll joined the European Federation of Pharmaceutical Industries and Associations (EFPIA) as Director General in April 2017. EFPIA represents the pharmaceutical industry operating in Europe. Together with its direct membership of 40 leading pharmaceutical companies, 33 national associations representing over 1,900 companies and in collaboration with health and research players, EFPIA's mission is to create an environment that enables its members to innovate, discover, develop and deliver new therapies and vaccines for people across Europe, as well as contribute to the European economy.

Prior to joining EFPIA, between 2010 and 2017, Ms Moll was the Secretary General of EuropaBio, ranked as the most effective European Trade Association in Brussels in 2013. She spent over 20 years working for the biotech industry at EU and national level in associations and corporate positions and held the position of Chair and Vice Chair of the International Council of Biotech Associations (ICBA).

In 2013, Ms Moll won the Technovisionaries Women Innovation Award organised by Women & Technologies® while in 2009, she and the Green Biotech Team of EuropaBio were presented with the Leadership and Excellence in Advancing Ag-Biotech and Food Issues Award. Ms Moll was also named one of the 15 leading women in biotech in Europe in 2017.

Ms Moll holds an Honours Degree in Biochemistry and Biotechnology from St Andrews University, Scotland.

Timothy Newton

Timothy Newton

Founder and CEO
Reflection Therapeutics

Timothy Newton is the Founder and CEO of Reflection Therapeutics, a biotechnology company utilising regulatory T cells to treat neurodegeneration.  Reflection Therapeutics is part of the Accelerate@Babraham programme based in Cambridge, UK, and is backed by Deep Science Ventures. Prior to founding Reflection Therapeutics, Dr Newton worked as an analyst at Deep Science Ventures.  This work allowed him to examine the best approaches to drug discovery in neurodegeneration, where he identified neuroinflammation as the greatest opportunity in the field. This conclusion is backed by many years’ experience researching neurodegenerative diseases, including work at Alzheimer’s Research UK’s drug discovery institute in Cambridge, UK.  Dr Newton has been commissioned by the British Journal of Pharmacology to author a review on drug discovery strategies in neurodegeneration, focussing on the proteostasis network.  He has also published work on the genetic origins of rare motor neuron diseases and the impact of statins on rare dementias. Dr Newton holds an MBiochem from the University of Oxford and an Mres and PhD in Medicine from the University of Cambridge.

Michael Oberreiter

Michael Oberreiter

Head of Global Access
Roche

Michael Oberreiter is the Global Head of Access at Roche. He has been involved in the field of health economics, health systems development and health policy for over 20 years. His experience spans across different therapeutic areas and countries – including Austria, Germany, Hungary and Asia Pacific (APAC) where he was responsible for driving the development of policy and access strategies to demonstrate the value of, and broaden sustainable access to Roche products in the region. Mr Oberreiter joined Roche in 2013 with the task of managing market access after the introduction of the Pharmaceuticals Market Reorganisation Act (AMNOG) in Germany. Prior to this, he held a number of senior positions within the research based and the generic industry, including General Secretary of national industry associations. He has held senior commercial positions in several companies (ratiopharm, Pfizer, Wyeth) related to access and was responsible for developing and implementing market access strategies for established brands and pipeline products and for reimbursement negotiations with payers. He also led stakeholder management and led cross-functional access and patient advocacy teams. His main areas of professional interest comprise healthcare system analysis, funding and organisation of health services and value-based pricing and reimbursement. He is an Industrial economist by training and completed post-graduate diploma and Master studies in International Politics and Communications.

Tom O'Leary

Tom O'Leary

Chief Information Oficer
ICON

Tom O'Leary is ICON’s Chief Information Officer and has over 20 years of experience in the pharmaceutical industry. He joined the company in 2001 as Manager of Data Management and has since held various leadership positions at the company.

Prior to ICON, Mr O’Leary worked for SmithKline Beecham, later GlaxoSmithKline, and held positions in Data Management, Project Management and Resource Management. Mr O’Leary holds a Degree in Medicinal Chemistry and a Master’s in Data Management from Kingston University in Surrey, He is a Member of the Royal Society of Chemistry. In 2018 he was recognised as 'CIO of the Year' by the Irish Tech Awards.

Kevin Outterson

Kevin Outterson

Executive Director
CARB-X

Professor Outterson teaches healthcare law at Boston University, where he co-directs the Health Law Programme.  He serves as the Executive Director and Principal Investigator for CARB-X, a $540m international public-private partnership to accelerate global antibacterial innovation.  Key partners in CARB-X include the US Government (BARDA & NIAID), the Wellcome Trust, the UK Government (GAMRIF, DHSC), the German Federal Ministry of Education and Research, and the Bill & Melinda Gates Foundation. Professor Outterson’s research work focuses on the law and economics of antimicrobial resistance. He was a senior consultant on the Eastern Research Group study on antibiotic markets for FDA/HHS. Starting in October 2014, he joined DRIVE-AB, a three-year €9mn project on antibiotic business models sponsored by the European Union’s Innovative Medicines Initiative.  Professor Outterson also serves on the Advisory Panel for the Longitude Prize for an inexpensive rapid point-of-care antibiotic diagnostic.  Professor Outterson was given the 2015 Leadership Award by the Alliance for the Prudent Use of Antibiotics for his research and advocacy work.  He has testified before Congress, Parliamentary working groups, WHO, and several state legislatures.  Since August 2016, he leads CARB-X, the world’s largest and most innovative antibiotic accelerator.

John Oyler

John Oyler

Chairman and Co-Founder
BeiGene

John Oyler is Chairman and Co-Founder, and has served as Chief Executive Officer and a member of our Board of Directors of BeiGene since 2010. From 2005 to 2009, Mr Oyler served as President and Chief Executive Officer of BioDuro, LLC, a drug discovery outsourcing company which was acquired by Pharmaceutical Product Development Inc. in 2010. From 2002 to 2004, Mr Oyler served as Chief Executive Officer of Galenea Corp., a biopharmaceutical company dedicated to the discovery of novel therapies for central nervous system diseases which initially were developed at Massachusetts Institute of Technology. From 1997 to 2002, Mr Oyler was a Founder and the President of Telephia, Inc. which was sold to The Nielsen Company in 2007. From 1997 to 1998, Mr Oyler served as Co-Chief Executive Officer of Genta Incorporated (NASDAQ: GNTA), an oncology-focused biopharmaceutical company. Mr Oyler began his career as a management consultant at McKinsey & Company. Mr Oyler received his B.S. from Massachusetts Institute of Technology and MBA from Stanford University.

Giles Platford

Giles Platford

President, Europe & Canada
Takeda Pharmaceuticals

Giles Platford is President of Europe & Canada for Takeda. He is also a Corporate Officer and a member of Takeda’s Executive Team reporting to the Company’s CEO & President. A seasoned industry leader with over 15 years of pharmaceutical experience, Mr Platford was formerly President of Emerging Markets for Takeda, where he oversaw the launch of Takeda’s innovative pipeline across the region, and led the design and roll-out of Takeda’s global Access to Medicines program. Previously, Mr Platford headed the Middle East, Turkey and Africa region where he strengthened controls and compliance whilst re-engineering the business for growth. He also held various leadership positions including General Manager Brazil, where he transformed Takeda into a top 10 pharma industry player, being externally recognised for the first time as one of the country’s top employers and best companies to work for. Before joining Takeda in 2009, Mr Platford spent eight years in Asia Pacific, where he assumed a number of Business Development, Commercial and General Management roles. A UK national, Mr Platford holds a BA Honors degree in Business and Marketing Management from Oxford Brookes University.

Andrew Radin

Andrew Radin

Co-founder and CEO
twoXAR

Andrew Radin is Co-founder and Chief Executive Officer of twoXAR, an artificial intelligence-driven drug discovery company. The company leverages its computational platform to identify promising drug candidates, de-risks the opportunities through preclinical studies, and progresses drug candidates to the clinic through industry and investor partnerships. Mr Radin developed the company's proprietary algorithm and leads product development. Prior to co-founding twoXAR, He held Chief Technology Officer roles at several early stage companies where he managed teams as large as a hundred technologists distributed around the world. Mr Radin studied biomedical informatics in Stanford University's SCPD graduate program and holds Master of Science and Bachelor of Science degrees in Computer Science from Rochester Institute of Technology. 

Hanno Ronte

Hanno Ronte

Partner
Monitor Deloitte

Hanno Ronte is a Partner at Monitor Deloitte in London with 25 years of consulting experience.  His projects have focused on corporate strategy, business unit strategy, competitive response, marketing strategy and capability building as well as cost reduction and optimisation projects.  He has extensive experience in the healthcare and life science sector, working at board, business unit and brand level to drive change and impact in his clients.  He frequently facilitates senior executive meetings to drive decisions and create alignment.  Mr Ronte has a particular interest in how the life science industry has to increasingly operate across government, healthcare providers and payors. Prior to the merger with Deloitte in Jan 2013, Mr Ronte was part of the European management team for the Monitor Group, a member of the global Partnership Election Committee, and the head of the London office.  He has been at Monitor for 15 years, prior to which he worked at Braxton Associates / Deloitte Consulting. Mr Ronte has spoken at a number of international conferences on Real World Evidence and the future of the life science industry.  He has also co-authored a number of Deloitte Centre for Health Solutions publications. Mr Ronte holds a First Class BA Honours Degree in Economics from Jesus College Cambridge and an MBA with Distinction from London Business School.  He graduated as the top of his class from Vienna International School with an IB.

Serge Saxonov

Serge Saxonov

CEO, Co-Founder
10x Genomics

Serge Saxonov co-founded 10x Genomics in 2012 and has served as the CEO since its inception. He defined vision and strategy, contributed to core inventions, and led the company through multiple phases of rapid growth. In 2016, he was honored as one of Goldman Sachs 100 Most Intriguing Entrepreneurs of the Year. Prior to 10x Genomics, Dr Saxonov was Vice President of Applications at QuantaLife, where he was responsible for building content, driving new applications, and identifying key diagnostics opportunities for the core ddPCR technology. Before QuantaLife, Dr Saxonov was Founding Architect and Director of R&D at 23andMe. There he defined the initial conception of the product, built many elements of the technology, and drove strategy and execution of R&D functions as the company scaled. Dr Saxonov received a PhD in Biomedical Informatics from Stanford University and an A.B. in Applied Mathematics from Harvard College.

Karen Shaw Petrou

Karen Shaw Petrou

Co-Founder and Managing Director
Federal Financial Analytics

Karen Shaw Petrou is the Co-Founder and Managing Partner of Federal Financial Analytics, Inc., a privately-held company that since 1985 has provided analytical and advisory services on legislative, regulatory, and public-policy issues affecting financial services companies doing business in the US and abroad. Central banks, financial regulators, vendors, and financial-industry investors also rely on the firm’s advisory services. The firm’s practice is a unique blend of strategic advice and policy analysis that does not include lobbying or any other projects that would compromise its objectivity and independence.

Dr Petrou is a frequent speaker on topics affecting the financial services industry. She was dubbed by the American Banker in 2012 the “sharpest mind analysing banking policy today -- maybe ever.” In 2017, the International Monetary Fund referred to her as, “one of the most prominent non-governmental voices on financial regulation.”  In addition to presentations to the US Congress and US government agencies, she has spoken before such organisations as the Japanese Diet, the Office of the Comptroller of the Currency, various Federal Reserve Banks, the Economist’s Buttonwood conference, the Securities Industry and Financial Markets Association, the American Bankers Association, The Clearing House, the Financial Services Roundtable, the Institute of International Bankers, the Conference of State Bank Supervisors, the Brookings Institution, and many other industry, academic and policy- maker audiences. She has also authored numerous articles in professional publications such as the American Banker and International Economy, as well as general-interest media like The New York Times and Wall Street Journal.

Prior to founding her own firm in 1985, Dr Petrou worked in Washington as an officer at Bank of America, where she began her career in 1977. She is an Honours graduate in Political Science from Wellesley College and also was a special student in an Honours program at the Massachusetts Institute of Technology. She earned an MA in that subject from the University of California at Berkeley, and was a doctoral candidate there. She has served on the boards of banking organisations and sits as a director on the board of the Foundation Fighting Blindness and the Fidelco Guide Dog Foundation.

Thomas Senderovitz

Thomas Senderovitz

Director General
Danish Medicines Agency

Thomas Senderovitz is Director General of the Danish Medicines Agency.

He holds several posts in the EU Medicines Regulatory Network, including Chair of the Heads of Medicines Agencies Management Group and member of the European Medicines Agency’s Management Board, as well as a member of the EU Telematics Management Board.

In Denmark, he is member of the Steering Committee of the Center for Regulatory Science, University of Copenhagen, of the Reference Group for the Center of Public Leadership, University of Aarhus, of the Board of the Danish Strategy for Personalized Medicine and of the newly established Data Ethics Council.

Dr Senderovitz is a M.D. from the Faculty of Medicine, University of Copenhagen with more than 26 years’ experience from healthcare, the pharmaceutical industry, biotech, CRO and regulatory authorities. He has held several senior management positions within R&D in PAREXEL International, Grünenthal, UCB and Ferring – in addition, he has founded two biotech companies.

Badhri Srinivasan

Badhri Srinivasan

Head of Global Development Operations
Novartis

An industry veteran with more than 25 years of experience in clinical trial design and execution, Badhri Srinivasan is head of Global Development Operations for Novartis. Before joining Novartis, Mr Srinivasan was CEO and co-founder of Remarque Systems, a technology company that develops state-of-the-art disruptive technology solutions for the life sciences industry. Previously, he held several senior roles at Quintiles, most recently as Senior Vice President and Head of Global Delivery Network and Global Data and Safety Monitoring.

A member of multiple scientific, academic and executive advisory committees, Mr Srinivasan has represented numerous pharma companies at the FDA, EMA and MHRA. Also, a member of the board of TransCelerate and Alliance for Clinical Research Excellence and Safety, he has been named to PharmaVOICE 100, the magazine’s list of the 100 most inspiring people in the life sciences industry. Mr Srinivasan holds an ABD in Biostatistics from the University of North Carolina, Chapel Hill, and a Master’s degree in Mathematical Statistics from Bangalore University, India.

Richard Torbett

Richard Torbett

Executive Director, Commercial Policy: UK and International
Association of the British Pharmaceutical Industry (ABPI)

Richard Torbett joined ABPI in July 2015 and is responsible for pricing and commercial policy, including the voluntary scheme for pricing and access to branded medicines, health technology assessment; as well as the organisation’s partnership activities with the NHS throughout the UK. Richard also leads ABPI’s involvement in international policy issues. 

Dr Torbett has spent the last 13 years working in the pharmaceutical industry. Immediately prior to joining ABPI he was the Chief Economist at the European Federation of Pharmaceutical Industries and Associations (EFPIA) where he was responsible for strategy as well as economic analysis and EFPIA’s relations with international economic institutions. He also spent six years at Pfizer, most recently as Senior Director and Head of International Affairs.

Prior to joining the pharmaceutical industry, Dr Torbett worked as a government economist. As a Government official, he held a number of posts at DTI, the Cabinet Office and the European Commission.

Dr Torbett regularly participates in the public policy debate on the future of healthcare, innovation and the role of pharmaceuticals. He has also contributed to academic work on public finances and the relationship between health and economic growth.

Mark Trusheim

Mark Trusheim

Strategic Director, NEWDIGS
MIT Center for Biomedical Innovation

Mark Trusheim is Strategic Director, MIT NEWDIGS where he also co-leads the Financing and reimbursement of Cures in the US (FoCUS) Project; and a Visiting Scientist at the MIT Sloan School of Management. Through MIT he has also served as a Special Government Employee for the FDA’s Office of the Commissioner. Mr Trusheim’s research focuses on the economics of biomedical innovation, especially precision financing for patient access, precision medicine, adaptive pathways, platform trials and digital health advances. Prior to MIT, his career spanned big data at Kenan Systems, marketing at Searle Pharmaceuticals, eHealth as Vice President of Monsanto Health Solutions, genomics as President of Cereon Genomics, and policy as the President of the Massachusetts Biotechnology Council. He holds degrees in Chemistry from Stanford University and Management from MIT.

Dan Vahdat

Dan Vahdat

CEO
Medopad

Dan Vahdat is an award-winning innovator, CEO and founder of Medopad, a British HealthTech AI company with a vision to create a world where people can live longer. Headquartered in London with offices in US and China, Medopad transforms how healthcare providers, doctors and patients connect with each other. The company’s remote patient monitoring apps and advanced analytics unite to provide a more efficient, personalised health experience for patients with rare and chronic conditions. Medopad’s clients include hospitals, global pharmaceutical organisations, insurance companies, and governments. Mr Vahdat accompanied UK Prime Minister Theresa May on her state visit to China in January and struck $140m worth of deals to improve Chinese patient care. Following the trip, Medopad and Tencent partnered to work on projects to potentially predict life-threatening complications across different disease indications. Medopad has been named a $1bn HealthTech company in the making by KPMG. Mr Vahdat was recently awarded CEO of the Year 2018 at WEBIT Global Summit . He pursued his PhD in Bioengineering at Johns Hopkins University and University, leaving before completion to start Medopad.

Francesca Wuttke

Francesca Wuttke

Chief Digital Officer
Almirall

Francesca Domenech Wuttke, PhD is the Chief Digital Officer of Almirall where she is developing and executing an end-to-end company-wide digital transformation. She is responsible for finding use cases across R&D, commercial, manufacturing, finance, legal and HR to apply digital solutions and services to bring efficiencies in terms of time and cost and to open up new business channels for Almirall. Dr Wuttke brings with her broad drug development and healthcare expertise in both the US and Europe, with over 20 years of clinical, commercial, strategic and transactional experience. She has worked with diverse organisations including start-ups, consulting, large and specialty pharma as well as academia. Most recently, she led European investments as Managing Director for the MSD Global Health Innovation Fund, LLC. Previously Dr  Wuttke led Almirall´s Corporate Development Strategy team to transact on both medical device and pharma M&A opportunities with a new and targeted focus for the company. Prior to that, Dr Wuttke worked at Novartis where she was responsible for two Cell and Gene therapy opportunities that were successfully brought into the organisation as well as managing the strategy and commercialisation for the existing portfolio of cell therapy assets. Dr Wuttke holds a PhD in Pharmacology from Weill Cornell Graduate School of Medical Sciences and a BA from Cornell University College of Arts and Sciences.

fallback

CHAIR (3)

Sarah  Neville

Sarah Neville

Global Pharmaceuticals Editor
Financial Times

Sarah Neville began her career on local and regional newspapers, eventually becoming political editor of the Yorkshire Post. In 1995 she was awarded the Laurence Stern Fellowship on the Washington Post. She joined the Financial Times in 2001 and has since held a series of senior roles, including Weekend News Editor, Analysis Editor, UK News Editor and public policy editor in 2011. She was appointed Pharmaceuticals Correspondent in 2016.

Hannah Kuchler

Hannah Kuchler

US Pharma and Biotech Correspondent
Financial Times

Hannah Kuchler is US Pharma and Biotech Correspondent for the Financial Times, with a particular focus on how technology is transforming healthcare. For five years, Ms Kuchler served as FT’s San Francisco Correspondent where she covered Silicon Valley and technology with a focus on social media and cyber security. Ms Kuchler was previously a London-based UK news reporter for the FT, covering British politics and general UK news. Prior to this, she worked on the FT’s newsdesk, as Asia Correspondent for FT Tilt in Hong Kong, and covered US markets in New York.  Before joining the FT in 2009, Ms Kuchler was the Editor of The Oxford Student and won the Guardian’s Student Reporter of the Year award in 2008. She holds a Bachelor’s degree in Modern History from Balliol College, Oxford.

Greg Reh

Greg Reh

Global Life Sciences & Health Care Industry Leader
Deloitte

Greg Reh is a Global Life Sciences & Health Care Industry Leader and the Global Life Sciences Sector Leader for Deloitte Touche Tohmatsu Limited (Deloitte). He is also the life sciences sector leader for Deloitte in the United States. He has more than 25 years of experience in the life sciences, process manufacturing, consumer and government sectors. His consulting career has spanned such topics as technology strategy, integration solution development and implementation of emerging and disruptive technology. His clients have included multinational pharmaceutical, biotechnology and chemical manufacturing organizations where he successfully led consulting services in support of regulatory, clinical, commercialization and manufacturing operations.

Prior to his consulting career Greg held positions at a government research lab, where he led teams in the design and development of life support devices; and was a lecturer at the University of Pennsylvania.

Advisory Board (11)

Virginia Acha

Virginia Acha

Executive Director-Global Regulatory Policy, R&D Innovation Centre
MSD

Virginia (Ginny) Acha has worked in industry and academia throughout her career, combining interests in science policy research and innovation performance within and across organisations.  She recently joined MSD to lead regulatory policy efforts for innovation that will lead to better treatment for patients in Europe, the Middle East, Africa and Asia.  In particular, she is supporting work on real world evidence and integrated evidence generation. Before joining MSD, Dr Acha was the senior spokesman for the industry in the UK for research, medical and innovation policy.  She was responsible for ABPI’s work on Brexit for the life sciences sector.  Previously, Dr Acha worked for Amgen in global regulatory policy and for Pfizer working on policy development in science and innovation in healthcare. 

Lisa  Anson

Lisa Anson

CEO
Redx Pharma

Lisa Anson is Chief Executive Officer of Redx Pharma plc, appointed in June 2018. She held the post of President of AstraZeneca UK since 2012 and has significant leadership experience in pharmaceuticals. Over a 20 year career at AstraZeneca plc, Ms Anson held a number of senior management roles in both the US and the UK including Global Vice President, Oncology and as Vice President of emerging brands where she worked closely with the Research and Development teams. She joined Zeneca Pharmaceuticals (USA) in 1998 as a business development manager. Prior to this she worked for Salick Health Care (now Aptium), a California based cancer disease management company. Her first position upon graduating from university was with KPMG in London as a management consultant

Ms Anson is President of the Association of the British Pharmaceutical Industry (ABPI) a position from which she will step down in 2018. She has been a Board member of the ABPI since 2012 where she has chaired a number of UK industry committees and worked closely with Government.

Ms Anson holds an MBA (awarded with distinction) from INSEAD, France and a First Class honours degree in Natural Sciences from Cambridge University in the UK. 

Alexandra Bause

Alexandra Bause

Founding Partner
Apollo Ventures

Alexandra Bause is a founding member and partner at Apollo Ventures, a biotech company builder and investment fund focused on developing interventions to improve human health and longevity. At Apollo, Ms Buase is leading the venture creation programmes that aim to found new biotech startups targeting the ageing process at a molecular level. She is also managing the pipeline and diligence process for external investment opportunities, predominantly focusing on preclinical-stage biotech companies. 

Before joining Apollo Ventures, Ms Bause worked with The Boston Consulting Group where she specialised in biopharma strategy, market assessment and asset diligence. Her PhD studies at Harvard Medical School were focused on investigating the molecular mechanisms that contribute to cellular aging and could be targeted to increase mammalian health span. She is also a trained pharmacist with expertise in pharmaceutics and pharmacology.

Jeanne Bolger

Jeanne Bolger

Vice President, Venture Investments
Johnson & Johnson Development Corporation (JJDC)
Richard  Mason

Richard Mason

Co-Founder
The Foundation Institute for 21st Century Medicine (C21Med)

Richard Mason, MD, is Co-Founder of The Foundation Institute for 21st Century Medicine (‘C21Med’), an initiative of venture capital firm Medicxi

Dr. Mason served as Head of Johnson & Johnson’s London Innovation Centre from October 2015 to April 2018, where he was responsible for Johnson & Johnson Innovation within the EMEA region. In this role, Dr. Mason led a team of transaction and scientific innovation experts to identify and develop a diverse portfolio of early-stage partnerships and investments across all three sectors of J&J.
 
Prior to joining J&J, Dr Mason was CEO of a venture-backed biotechnology startup, XO1 Ltd. until the company was acquired by Janssen Pharmaceuticals (a subsidiary of J&J) in March 2015. Prior to that, he was Head of Strategy and Business Development and member of Executive Leadership Team at specialty pharmaceutical and medical device company BTG Plc (LON: BTG), where he led its transformation into a leading interventional medicine company through multiple acquisitions including Ekos Corporation, Biocompatibles Plc, and MDS Nordion’s Therasphere business. Dr.Mason also served as an Executive-in-Residence for Advent Venture Partners where he served as a turnaround CEO for several portfolio companies. Prior to that he was Senior Vice President, Business Development at Cambridge Antibody Technology (CAT) and member of the CAT Executive Leadership Team.
 
Dr. Mason trained in Medicine at the St Bartholomew’s Hospital Medical College and worked in clinical practice in internal medicine before entering the biotechnology industry. He also has a degree in immunology from University College, London and an MBA from The Judge Business School, University of Cambridge, where he is currently a Fellow in Healthcare Management.

Mark Samuels

Mark Samuels

Chief Business & Strategy Officer
Medicines Discovery Catapult

Mark Samuels is Chief Business & Strategy Officer at the Medicines Discovery Catapult. In this role, he is responsible for business development, strategy, communications and research consortia. Previously, Mr Samuels founded the national Office for Clinical Research Infrastructure and was a founder member of the NIHR Strategy Board. With £1.1bn annual budget, the NIHR is responsible for NHS research across England. Mr Samuels also worked with Number 10 on David Cameron’s strategy for life sciences. At HIHR he established the organisation’s Translational Research Collaborations and chaired the creation of the UK’s Stem Cell Transplant Clinical Trials Partnership. Before NIHR, Mr Samuels was an executive at Roche Diagnostics. Representing the UK diagnostics industry, he co-chaired with Sir Andrew Dillon creation of the programme for NICE to evaluate diagnostics and medical devices. Educated at QMUL and Saïd Business School, Mr Samuels holds a Policy Fellowship at Cambridge University.

Mike Standing

Mike Standing

EMEA Life Sciences and Healthcare Lead
Deloitte

Mike Standing is the Life Sciences and Healthcare industry leader for Deloitte for EMEA. Mr Standing has consulted to leading pharmaceutical and healthcare organisations in Europe, US and China for over 20 years, focusing on commercial strategy, operations and R&D productivity. In addition, he is currently leading major programmes to understand how real world evidence can transform health outcomes and productivity. He also advises governments on building healthcare clusters and is a member of the UK's Global Medical Excellence Cluster (GMEC) Advisory Board. Prior to joining Deloitte, Mr Standing was Co-Head of Life Sciences for the Monitor Group and Global Head of Capgemini's Life Sciences business. He is a graduate of Durham and Cambridge Universities and is based in London.

Andy Garrett

Andy Garrett

Executive Vice President, Scientific Operations
ICON

Andrew Garrett is Executive Vice President Scientific Operations at ICON, responsible for strategic direction and operational execution of ICON’s Global Scientific Operations. He was Chair and Founder of the Royal Statistical Society’s (RSS) Data Science Section having previously been VP/Honorary Secretary of the organisation, and Chair of its Long Term Strategy Group. He was previously a Board member of the UK’s Administrative Data Research Network and is currently a member of UKSA’s Research Accreditation Panel that oversees the approval of research projects in accordance with the Digital Economy Act 2018. He has worked extensively in the area of rare diseases and has a portfolio of published papers on the topics of non-inferiority trials, subgroup analysis, data transparency and modelling and simulation. Dr Garrett has a BSc in Economics, an MSc in Medical Statistics and a PhD in Applied Statistics.

Sarah Maxfield

Sarah Maxfield

VP of Sales
Europe & Asia at FUJIFILM Diosynth Biotechnologies
Faraz Kermani

Faraz Kermani

Sr. Manager European Commercial Communications, External Communications
CSL Behring
Chris Surridge

Chris Surridge

Director of Strategy and Commercial Excellence
Mundipharma
fallback

Agenda - 11th Nov

  • 1:15pm
    Opening Remarks from the Chair
  • 1:20pm
    Keynote Address/Interview

    Stefan Oelrich, Member of the Management Board and President, Pharmaceuticals, Bayer

  • 1:35pm
    Panel: Who Owns the Patient? The Disruption to Come

    As healthcare increasingly moves from treatment to prevention, pharma companies encounter a growing number of ‘new entrants’ with whom they will compete for patients’ loyalty and data. Big tech companies, as well as innovative new start-ups are at the centre of the shift, using complex digital tools and algorithms to help patients stay healthy and manage their conditions. Retailers, insurers and consumer brands are also entering the fray, while pharma companies are making tentative first steps with their own versions of disease management technologies and services. Gaining access to patient data is key. At a time when concerns regarding data quality, integrity and the privacy of patient data are paramount, building robust evidence to back health claims, as well as relationships with patients based on trust will be central to success.

    • What role will pharma play in this population health space?
    • Will patients trust consumer and tech brands over pharma?
    • How robust are these health algorithms, and how will digital apps and therapies stack up against growing demand for evidence and validation? Or are lifestyle interventions a ’new kind of medicine’ which can be held to different standards of evidence?
    • What will it mean for pharma when more health data will reside outside the traditional healthcare system than within it?

    Camilla Sylvest, Executive Vice President, Commercial Strategy and Corporate Affairs, Novo Nordisk
    Lord Drayson, PhD, CEO, Sensyne Health
    Eddie Martucci, CEO and Co-Founder, Akili Interactive
    Hanno Ronte, Partner, Deloitte
    Dan Vahdat, Founder, Medopad

  • 2:25pm
    Keynote Address/ Interview

    David Meek, CEO, Ipsen

  • 2:40pm
    Networking Coffee Break

     

  • 3:00pm
    Keynote Interview

    Bill Campbell, Executive Vice President and Chief Commercial Officer, CSL Behring

  • 3:15pm
    Turning the Big Pharma Ship - Transformation and Talent Strategies

    Pharma companies are likely to undergo a significant shake-up as they position themselves for a rapidly changing healthcare landscape. Success, to a large extent, will depend on their ability to attract, develop and retain high-performance talent from across a wide range of industries, develop new operational and organisational models and break down the silos inhibiting innovation.

    • How are pharma companies managing the transformation in terms of governance, operational and organisational change?
    • How can pharma companies foster innovation, entrepreneurial spirit and address the calling to ‘innovative like a start-up’?
    • What are the leading-edge strategies for recruitment, development and retention success?
    • How do you create a value proposition for pharma that will attract millennials and much-needed data scientists? How do you prevent new talent ‘going native’?
    • How are global workforce trends impacting pharma (robotics, millennials, remote working) and what will the pharma company of the future look like?
    • How will the transition of leadership talent from pharma to biotech impact the future talent pipeline of the industry?

    Session keynote: Marie-France Tschudin, President, Pharmaceuticals, Novartis
    Mark Howells, VP Talent and DevelopmentAstraZeneca
    Bahija Jallal, CEO, Immunocore
    Moderator: Greg Reh,  Global Life Sciences & Health Care Industry Leader, Deloitte

  • 4:05pm
    Keynote Interview

    Tom O'Leary, Chief Information Officer, ICON

  • 4:20pm
    Panel: Chief Digital Officer Forum

    Chief Digital Officers (CDOs), often appointed from other industries, provide a unique perspective on the transformation underway in the industry. What have been their experiences to date, and what have been the obstacles they have experienced along the way? How are they building digital pharma companies? How are they dealing with the transition from consumer, data and other industries to the world of pharma, and how has their role evolved? What are their observations regarding the industry, the transformation that is needed, and the way ahead?

    Francesca Wuttke Chief Digital Officer, Almirall
    Karenann Terrell, Chief Digital Officer and Chief Technology Officer, GlaxoSmithKline

  • 5:10pm
    Closing Remarks from the Chair

Agenda - 12th Nov

  • 9:05am
    Keynote Address/ Interview/Presentation

    Joaquin Duato, Vice Chairman of the Executive Committee Johnson & Johnson

  • 9:20am
    Panel: Resolving Pharma’s Pricing Conundrum: A New Prescription

    From the US President’s Pricing Blueprint to moves towards EU-wide drug procurement, pressure on the industry’s pricing model is growing. The advent of ultra-expensive and potentially curative gene and cell therapies, meanwhile, is also adding to the momentum for change. The status quo is no longer working. If the industry is to remain in the driving seat, it is going to have to accept that new ways of funding the industry, and innovative pricing models will be necessary. This will have a potentially transformative impact on the economic model of the industry and the way it funds R&D. What would a sustainable innovation funding model look like?

    • Are subscription / Netflix-type pricing models the future?
    • Will outcome-based pricing become the norm? What’s the devil in the detail? How are the pioneers of outcome-based models dealing with the complexity?
    • How do you price and finance a cure? What could be the role for reinsurance and other innovative pricing models?
    • How do you price digital therapies? Offering the potential for ‘cures’, should they be priced ‘just like a drug’?

    Mark Trusheim, Strategic Director, NEWDIGS, MIT Centre for Biomedical Innovation
    Yvonne Greenstreet, Chief Operating Officer, Alnylam
    Justin McCarthy, Senior Vice President, Patient and Health Impact Group, Pfizer
    Michael Oberreiter, Global Head of Access, Roche 
    Moderator: Greg Reh,  Global Life Sciences & Health Care Industry Leader, Deloitte

  • 10:05am
    Alternative Funding Models for R&D / Financing Unmet Medical Needs
    • Given the inflationary impact of pharma’s current high-risk, high-reward funding model, are there alternative and better ways of funding drug innovation? Is there a need for governments to be involved, particularly in ensuring unmet needs are financed?
    • Does recent experience with antimicrobial resistance (AMR) show the way ahead in terms of innovative funding that could be applied to many other diseases? What is the evidence that government involvement and risk-taking yields faster drugs at lower prices?
    • What could be the role of prize funds, venture philanthropy and patient financing?

    Karen Shaw Petrou, Co-Founder and Managing Partner, Federal Financial Analytics
    Kevin Outterson, Executive Director and Principal Investigator, CARB-X
    Angus Grant, CEO, Dementia Discovery Fund (DDF)
    Pierre Meulien, Executive Director, Innovative Medicines Initiative (IMI)

     

  • 10:50am
    Keynote Interview

    Kare Schultz, President and CEO, Teva

  • 11:05am
    Networking Coffee Break
  • 11:25am
    Panel: Intellectual Property: Is the Current System Still Fit for Purpose?

    In the distant past, society decided to strike a Grand Bargain of IP, providing innovators a monopoly for a set number of years to recover costs and ensure a return, thus striking a balance between incentives and societal benefit. Some allege, though, that pharma has found ways to unfairly manipulate the IP system, keeping costs sky-high for decades. And pressure is steadily mounting for change. Can industry players compromise before the heavy hand of government steps in?

  • 11:55am
    Keynote Interview

    Heather Bresch, CEO, Mylan

  • 12:10pm
    Rewarding Innovation: What is the Regulation we Need?

    Regulation matters. The global financial crisis illustrates what can happen when regulation fails to keep track of changes in the industry. For life sciences, this means keeping up to date with advances in technologies including digital and AI, as well as advances in cutting-edge science to include cell and gene therapies. And it also means knowing what society wants from regulation of the industry - finding the bright balance between safety and ‘right to try’, for instance. With a change of guard underway at the FDA. the possibility of EU health directorate re-opening the regulatory rule book and a review of regulatory science underway, it is opportune to ask what kind of regulation we want in order to ensure we get the innovation we need.

    Virginia Acha, Global Regulatory Policy for Europe, Middle East, Africa and Asia, MSD
    Thomas Senderovitz, Director General, Danish Medicines Agency 
    Moderator: Greg Reh,  Global Life Sciences & Health Care Industry Leader, Deloitte

  • 12:50pm
    Keynote Interview/Presentation
  • 1:05pm
    Lunch
  • 2:05pm
    Panel: Digital R&D: AI - The Reckoning?

    The burgeoning field of AI is attracting increasing amounts of investment from pharma companies who are putting their faith in the technology's ability to deliver the next big leaps in drug development. Opinions differ, however, on the extent that AI will bring down costs in R&D or find cures, with no drugs yet discovered or commercialised with AI. The complexities of implementation, the issues of data collection, quality and the need for scale, meanwhile, are often underplayed amidst the hype. Where will AI add value to pharma R&D, and where will it not? Are current algorithms focusing on the right things? How are standalone AI drug companies doing things differently, and when might we see the first AI-developed drug?

    Badhri Srinivasan, Head, Global Development Operations, Novartis
    Jackie Hunter, Board Director, BenevolentAI
    Andrew Radin, Co-founder and CEO, twoXAR
    Andrew Garrett, Executive Vice President Scientific Operations, ICON

  • 2:55pm
    Keynote Interview/Presentation
  • 3:10pm
    Panel: The Global Competition for Investment: How Will the Clusters Fare?
    • How will Brexit impact the competitive position of the UK as a leading global science hub?
    • Is the UK’s Industrial Strategy a sufficient response, or will the likely impact of Brexit outweigh the potential benefits? What does the UK need to do to stay ahead?
    • Will the US maintain its status as the world leader in R&D expenditure in pharma, in patents and as a centre of pharma innovation? How will the expected lowering of drug prices and NIH support impact its position?
    • Will China steal a lead by virtue of largely laissez-faire approach to regulation and growing prowess in AI, genome sequencing and advanced cell and gene therapies?
    • How are investors viewing the relative competitiveness of the clusters in view of these transitions underway?
    • The new cluster success stories: how are they attracting investment?

    Richard Torbett, Executive Director, Commercial Policy: UK and International, Association of the British Pharmaceutical Industry (ABPI)    
    Brad Loncar, CEO, Loncar Investments
    John Oyler, Chairman and Co-Founder and CEO, BeiGene

  • 3:50pm
    Into the Den: The Next Big Thing? Innovation on the Frontiers or Science, Medicine and Technology

    Where is science and technology taking the future of medicine? What are the emerging areas, and as yet little known areas of therapeutic focus (targets, modalities, technologies) which could have a big impact on patient outcomes and become the potential growth drivers of the future? What is hype and what is real? Is the industry doing enough to leverage the experience and expertise of diverse industries and domains including engineering, mathematics, physics, for instance, and what are the possibilities? This session will feature a number of quick-fire presentations of potentially game-changing science and technologies, followed by a panel discussion of leading VCs and an audience vote on likely winners.

    Serge Saxonov, CEO, Co-Founder, 10X Genomics
    Timothy Newton, Founder and CEO, Reflection Therapeutics
    Alexis Borisy, Partner, Third Rock Ventures
    Mark Hammond, Founding Partner, Deep Science Ventures
    Alexandra Bause, Founding Partner, Apollo Ventures

  • 4:50pm
    In Conclusion: Can Pharma do Better at Telling its Story?

    For an industry whose business is saving lives and curing diseases, pharma has an unenviable reputation, even when compared to other players in the healthcare system. Meanwhile, the tech companies with which pharma must increasing compete or collaborate enjoy positive perceptions as ‘disruptors’ and a ‘constructive force for good’ for consumers. With pharma under siege on a multitude of fronts, does the industry need to get better at communicating its value story? How did the industry get here, and how can it rebuild trust? Can a focus on closer partnerships with HCP/health service providers based on improving outcomes, for instance, help win trust and nurture support? How can the industry build trust and be seen as a partner of choice with others in the ever-extending industry value chain and with patients?

    Sir Harpal Kumar Head of Innovation, Johnson & Johnson EMEA
    Chris Boerner, Executive Vice President, Chief Commercial Officer, Bristol-Myers Squibb
    Nathalie Moll, Director General, European Federation of Pharmaceutical Industries and Associations (EFPIA)
    Giles Platford, President, Europe and Canada,Takeda Pharmaceuticals

  • 5:25pm
    Closing Remarks from the Chair

WHY ATTEND?

  • Debate the role of super clusters and industrial strategy in creating a ‘big bang’ in life sciences
  • Discover how China’s novel approaches to R&D, data and digital health are creating innovate treatment and service models
  • Discuss what it takes for pharma to win in population health management and the business of prevention
  • Learn how innovative gene-based therapies are transforming the industry paradigm from treatment to cure and the pricing strategies to manage it.
  • Envision the future of diagnostics and personalised medicine
  • Hear from leading fund managers, corporate venturers, and other investors on where they are placing bets in pharma
  • Be part of the discussion on value and evidence and the challenge of managing the increasing volume and complexity of big data
fallback

WHO ATTENDS?

FT Live has a reputation for delivering very senior board level audiences to attend a wide range of world class thought-leadership events across the globe for nearly 40 years.

The FT Global Pharmaceutical and Biotechnology Conference will be attended by:

  • Pharmaceutical companies
  • Biotechnology companies
  • Diagnostic and medical device
  • CROs
  • Healthcare providers and insurers
  • Government healthcare departments, HTA’s and drug regulators
  • IT, big data and analytics providers
  • Health economists
  • Healthcare investment bankers, private equity
  • Patient representatives and NGOs
fallback

Attending companies

Sanofi • Roche • Bayer • AstraZeneca • Novartis • Merck Group • GlaxoSmithKline • Pfizer • Johnson & Johnson • Gilead Sciences •  Abbvie •  Allergan •  Teva Pharmaceutical Industries •  Celgene •  Astellas Pharma •  UCB Biopharma •  Bayer AG, Pharmaceuticals •  Sandoz •  BeiGene •  Ipsen •  Kymab •  Verona Pharma •  AstraZeneca Poland •  Teva Italia •  Acacia Pharma Group •  MNK Pharma, and many others.

fallback

SPONSORSHIP OPPORTUNITIES

  • Gain access to 350 Senior Executives from the International Pharmaceutical Industry, who will be attending the event;
  • Brand alignment with the FT and its unrivalled credibility;
  • Demonstrate thought leadership around the current critical issues affecting the healthcare industry;
  • Benefit from sustained international visibility through our advertising and marketing campaigns

Joe Hames

Commercial Manager, Global Industries

T: +44 (0)207 873 4551

M: +44 (0)791 329 2038

E: joe.hames@ft.com

fallback

FEES

Ticket

Fee

Super Early Bird Rate - Extended until 19 April

£1,799.00

Early Bird Rate - from 20 April - 30 May

£1,999.00

Standard Ticket Price - from 31 May onwards

£2,500.00

fallback

Presented By (1)

The Financial Times is one of the world’s leading business news organisations, recognised internationally for its authority, integrity and accuracy. The FT has a record paying readership of one million, three-quarters of which are digital subscriptions. It is part of Nikkei Inc., which provides a broad range of information, news and services for the global business community.

With the support of (1)

About Life Sciences and Health Care at Deloitte

Deloitte’s life sciences and health care (LSHC) industry group is composed of over 12,000 professionals in over 90 countries. These professionals understand the complexity of today’s life sciences and health care industry challenges, and provide clients with integrated, comprehensive services that meet their respective needs. In today’s environment, LSHC professionals from across the Deloitte network help companies to evolve in a changing marketplace, pursue new and innovative solutions, and sustain long-term profitability.

Global Clinical Research Partner (1)

ICON plc is a global provider of outsourced drug development and commercialisation solutions and services to pharmaceutical, biotechnology, medical device, and government and public health organisations. The company specialises in the strategic development, management and analysis of programs that support clinical development. ICON offers a full range of consulting, development and commercialisation services that help clients to accelerate the development of drugs and devices that save lives and improve quality of life.

ICON’s award-winning study execution capabilities have led to the approval of 18 of the world’s top 20 best-selling drugs.

With headquarters in Dublin, Ireland, ICON currently, operates from 93 locations in 37 countries and has approximately 13,650 employees. For further information please visit www.iconplc.com  Follow @iconplc on Twitter.

Lead Sponsor (2)

Associate Sponsor (1)

Association Partner (2)

The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.

Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 percent of all branded medicines used by the NHS and who are researching

and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.

Globally our industry is researching and developing more than 7,000 new medicines.

The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.​​

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 36 national associations and 40 leading pharmaceutical companies, EFPIA's mission is to create a collaborative environment that enables our members to innovate, discover, develop and deliver new therapies and vaccines for people across Europe, as well as contribute to the European economy. Our vision is for a healthier future for Europe. A future based on prevention, innovation, access to new treatments and better outcomes for patients. 

Venue

Royal Lancaster
Lancaster Terrace
London W2 2TY

United Kingdom

Tel: +44 207 551 6000

fallback

Contacts

Alexsandra Silva
Media Partner and Press Enquiries
Financial Times
Angela Letinov
Speaking Opportunities
Financial Times
Joe Hames
Sponsorship Opportunities
Financial Times
FT Live Delegate Services - EMEA
Delegate Booking and Registration Enquiries
Financial Times